trending Market Intelligence /marketintelligence/en/news-insights/trending/nik0xsehzcovcvvbziisyq2 content esgSubNav
In This List

Mylan, Biocon biosimilar approved in EU, Australia

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Mylan, Biocon biosimilar approved in EU, Australia

The European Commission approved Semglee, a biosimilar version of Sanofi's blockbuster drug Lantus.

Mylan NV and India-based biotechnology company Biocon Ltd. co-developed the medicine, intended for diabetes patients. The biosimilar was also approved in Australia.

The companies are also seeking approval for Semglee in U.S. and Canada.

Sanofi's Lantus generated €4.62 billion in global sales in 2017, the most in its diabetes franchise, which had combined sales of €6.40 billion the same year.